Rationalizing the Study of Intratumoral Immunotherapy in Breast Cancer Origin Liver Metastases
Jason Williams, MD, the director of Interventional Oncology and Immunotherapy oncologist at the Williams Cancer Institute, discusses a study in which an immunotherapy combination was administered intratumorally to patients with liver metastases linked to breast cancer, which he presented in a poster at the 2019 Society of Immunotherapy of Cancer Annual Meeting.
Jason Williams, MD, the director of Interventional Oncology and Immunotherapy at the Williams Cancer Institute, discusses a study in which an immunotherapy combination was administered intratumorally to patients with liver metastases linked to breast cancer, which he presented in a poster at the 2019 Society of Immunotherapy of Cancer (SITC) Annual Meeting.
A preclinical study in mouse models, which was led by Ronald Levy at Stanford University, showed synergy between α-OX40 and CpG. This study served as a rationale for Williams and his colleague to recreate the study in humans.
The immunotherapy combination used for the in-human study was α-OX40, CpG, ipilimumab (Yervoy), and ketorolac. Ipilimumab was added to the combination to address the complexity of treating human subjects compared with mouse subjects, and this improved the success rate of the study overall.
Managing HER2+ Early Breast Cancer: Insights and Future Horizons
November 28th 2023Sandra M. Swain, MD, FACP, FASCO, discusses the potential role for HER2-directed TKIs for the treatment of patients with early-stage HER2+ breast cancer and shares insights about emerging data that could impact the future treatment landscape.
Read More
Navigating HER2+ Early Breast Cancer: Insights Into the Current Treatment Landscape
November 28th 2023In this companion article, Sandra M. Swain, MD, FACP, FASCO, provides insights into effective management of patients with early-stage HER2+ breast cancer and reviews recent data in the evolving treatment landscape.
Read More
ctDNA Helps Identify Targets in HR+, HER2- Metastatic Breast Cancer
November 22nd 2023In the first article of a 2-part series, Hope S. Rugo, MD, FASCO, discusses how the use of circulating tumor DNA can aid in allowing next generation sequencing to better identify targets for patients with hormone receptor positive metastatic breast cancer.
Read More
